Mumbai: Agilus Diagnostics announced the launch of the Claudin 18.2 test, a ground-breaking diagnostic tool.
The Claudin 18.2 test is a diagnostic tool, that offers precise identification of the Claudin 18.2 protein, a crucial biomarker for gastric, pancreatic, and other cancers. By providing precise identification of this biomarker, this test empowers oncologists with critical insights, aiding in the identification of patients eligible for targeted therapies, improving outcomes in cancer treatment, and fostering personalised medicine.
Speaking on the launch, Dr Anand K, MD and CEO, Agilus Diagnostics, said, “Claudin 18.2 is an essential biomarker in modern oncology especially for gastric cancer patients. With an approved targeting antibody, this test not only enhances diagnostic precision but also bridges the gap to personalised medicine. It empowers clinicians to tailor treatments and significantly improve patient outcomes. Agilus Diagnostics is thrilled to bring this advanced tool to India and support oncologists and patients in the fight against cancer. We are committed to advancing diagnostics and healthcare by embracing the future of targeted therapies and personalised medicine, ensuring our efforts remain aligned with this transformative vision.”
Dr Kunal Sharma, Associate Director and HOD, Histopathology Center of Excellence, Agilus Diagnostics, commented, “In October 2024, the FDA approved zolbetuximab-clzb, a Claudin 18.2-directed antibody therapy, in combination with chemotherapy, for first-line treatment of adults with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancers that are CLDN18.2-positive. The FDA also approved VENTANA CLDN18 assay as a companion diagnostic test to identify patients eligible for treatment. Agilus Diagnostics’ launch of the FDA-approved Claudin 18.2 test in India aligns with these global developments, bringing advanced diagnostic and treatment opportunities to Indian oncology care.”
